|
V74763
|
Catumaxomab
|
509077-98-9 |
Catumaxomab is a trifunctional IgG2 antibody consisting of mouse and rat heavy and light chains that binds to human EpCAM and human CD3 receptors. |
|
V51153
|
Cevostamab (BFCR-4350A; RG-6160; RO-7187797)
|
2249888-53-5 |
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based BsAb that can inhibit the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. |
|
V74765
|
Dafsolimab (SPV-T3a)
|
2367001-71-4 |
Dafsolimab (SPV-T3a) is an IgG2a mouse monoclonal antibody (mAb) (anti-CD3). |
|
V74762
|
Epcoritamab (GEN3013)
|
2134641-34-0 |
Epcoritamab (GEN3013; Epkinly) is a bispecific IgG1 antibody that redirects T cells to CD3×CD20+ tumor cells. |
|
V51171
|
Flotetuzumab (MGD-006; S-80880)
|
1664355-28-5 |
Flotetuzumab (MGD006; S80880) is a dual-potential CD123/CD3 dual-affinity re-inhibitor (DART) superior. |
|
V51162
|
Foralumab (NI-0401)
|
946415-64-1 |
Foralumab (NI-0401) is a trauma-effective, humanized monoclonal antibody (mAb) that can inhibit CD3. |
|
V51155
|
Gresonitamab (AMG-910)
|
2413817-97-5 |
Gresonitamab (AMG 910) is a half-life extending (HLE) bipotential T cell engager (BiTE) precursor that can inhibit CD3-positive T cells and tumor cells expressing CLDN18.2. |
|
V51154
|
Muromonab
|
140608-64-6 |
Muromonab is a monoclonal antibody (mAb) that can inhibit CD3 capture. |
|
V51164
|
Obrindatamab (MGD-009)
|
2069959-72-2 |
Obrindatamab is a humanized anti-B7-H3/CD3 bipotent. |
|
V51161
|
Otelixizumab
|
881191-44-2 |
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody (mAb) utilized in study/research of type 1 diabetes. |
|
V51156
|
Pacanalotamab (AMG-420; BI-836909)
|
2251756-52-0 |
Pacanalotamab (AMG 420; BI-836909) is a dual-channel T cell reagent (BiTE) that activates BCMA and CD3ɛ. |
|
V51172
|
Pasotuxizumab (BAY-2010112)
|
1442657-12-6 |
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bipotent T cell engager (BiTE). |
|
V51170
|
Pavurutamab (AMG-701)
|
2250292-39-6 |
Pavurutamab (AMG-701) is an anti-CD3 and anti-B mature cell active (BCMA) dual-channel T-adhesive molecule. |
|
V51168
|
Solitomab (AMG-110)
|
1005198-65-1 |
Solitomab (AMG 110) is a bipotential anti-CD3 and anti-epithelial cell marker molecule (EpCAM) antibody. |
|
V51151
|
Talquetamab (JNJ-64407564)
|
2226212-40-2 |
Talquetamab (JNJ-64407564; Talvey) is a humanized bipotential binding antibody that binds to GPRC5D (G protein-coupled receptor family C5 group member D) and CD3 to induce T cell-mediated T cell recruitment and activation. |
|
V51150
|
Teclistamab
|
2119595-80-9 |
Teclistamab is a humanized BCMA and CD3 dual probe that recognizes BCMA on target cells and CD3 on T cells, inducing T cell-mediated cytotoxic effect, leading to activation of T cells and subsequent target cell mitochondria. |
|
V51152
|
Teplizumab (MGA-031; PRV-031)
|
876387-05-2 |
Teplizumab (MGA-031) is an Fc receptor-type, non-binding type monoclonal antibody (mAb) against human CD3. |
|
V51160
|
Tepoditamab (MCLA-117)
|
2044679-53-8 |
Tepoditamab (MCLA-117) is a dual lung cancer monoclonal antibody (mAb) that binds to CLEC12A on myeloid cells and CD3 on toxic T cells. |
|
V51165
|
Tidutamab (XmAb-18087)
|
2148354-90-7 |
Tidutamab (XmAb-18087) is a humanized and affinity-optimized dual transport binding antibody (bsAb) that can inhibit the SSTR2 domain and the T cell binding domain (CD3). |
|
V51167
|
Ubamatamab (REGN-4018)
|
2305629-50-7 |
Ubamatamab (REGN4018) is a human bispecific antibody targeting mucin 16 (MUC16) and CD3. |